Elevated levels of METTL1 correlates with poor prognosis of various cancers, including bladder cancer (BLCA) (18, 19), hepatocellular carcinoma (HCC) (15, 20), lung cancer (8), colon cancer (21), liver cancer (22), and glioma (23). This evidence concerns the gene METTL1 and bladder transitional cell carcinoma.